Clinical Research Directory
Browse clinical research sites, groups, and studies.
Fingolimod for Type 2 Diabetes Mellitus
Sponsor: General Hospital of Shenyang Military Region
Summary
The aim of this study is to explore the efficacy and safety of Fingoland in the treatment of type 2 diabetes. A total of 40 patients were randomly divided into two groups. One group was treated with fingolimod, another group was given guideline based treatment. The changes of islet function in patients with glycosylated hemoglobin, insulin and C-peptide were observed .
Official title: Fingolimod for Type 2 Diabetes Mellitus: a Pilot, Prospective, Randomized, and Open Label Single-center Study
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2022-03-15
Completion Date
2026-03-15
Last Updated
2025-08-21
Healthy Volunteers
No
Conditions
Interventions
Fingolimod
0.5mg daily for 90-180 days, in addition to guideline-based treatment for DM
guideline-based treatment for DM
guideline-based treatment for DM
Locations (1)
Department of Neurology, General Hospital of Northern Theater Command
Shenyang, China